Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) ranks second in sales growth and operating margin among peers. Despite outperforming Johnson & Johnson (JNJ) in growth and margins, Amgen trades at a lower P/E. Amgen's Q2 2026 report showed growth in key drugs like Repatha, but declines in Prolia and XGEVA due to biosimilar competition. The company raised its 2026 revenue guidance to $38.2B-$39.4B, with a midpoint of $38.8B, up from $37.8B. Operating expenses are expected to rise in Q3, potentially impacting margins.
How this was made
The 30-second read
Why it matters
Valuation comparison may influence short‑term sentiment but lacks a fresh catalyst.
Market read
Provides a valuation perspective for investors but does not introduce new material information.
What to watch
Potential upside from upcoming biosimilar competition mitigation and pipeline progress not covered in the article.
Background
The article revisits Amgen's Q2 2026 earnings call data released in August and compares its valuation to six large drugmakers.
Ticker impact
Article compares Amgen's valuation and growth metrics to peers, highlighting its lower P/E despite higher growth, and discusses Q2 2026 guidance.
potential downside as market may discount the stock for slower growth expectations
No new corporate event; the piece is a recap of already‑public Q2 guidance and peer data, so any price move would be speculative.
Market effects
Highlights valuation gaps in the large‑cap biotech sector, may prompt analysts to revisit peer multiples.
U.S. biotech stocks could see modest re‑rating based on the comparative analysis.
Limited; primarily U.S. investors focused on Amgen and its peers.
Counterpoint
Despite a higher P/E, Amgen's stronger growth could justify a premium if margin pressure eases.
Key entities
- CompanyAmgen
Biopharma firm with ticker AMGN.
